Peng L - Search Results

1

Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.

Zeng X, Peng L, Li J, Chen G, Tan C, Wang S, Wan X, Ouyang L, Zhao Z. Zeng X, et al. Among authors: peng l. Clin Ther. 2013 Jan;35(1):54-65. doi: 10.1016/j.clinthera.2012.12.013. Clin Ther. 2013. PMID: 23328269

2

The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience.

Zeng X, Karnon J, Wang S, Wu B, Wan X, Peng L. Zeng X, et al. Among authors: peng l. PLoS One. 2012;7(10):e48323. doi: 10.1371/journal.pone.0048323. Epub 2012 Oct 31. PLoS One. 2012. PMID: 23118985 Free PMC article.

3

A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer.

Wang S, Peng L, Li J, Zeng X, Ouyang L, Tan C, Lu Q. Wang S, et al. Among authors: peng l. PLoS One. 2013;8(3):e55917. doi: 10.1371/journal.pone.0055917. Epub 2013 Mar 8. PLoS One. 2013. PMID: 23520448 Free PMC article. Clinical Trial.

4

Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China.

Tan C, Peng L, Zeng X, Li J, Wan X, Chen G, Yi L, Luo X, Zhao Z. Tan C, et al. Among authors: peng l. PLoS One. 2013 Dec 10;8(12):e83396. doi: 10.1371/journal.pone.0083396. eCollection 2013. PLoS One. 2013. PMID: 24340099 Free PMC article.

5

Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.

Zeng X, Li J, Peng L, Wang Y, Tan C, Chen G, Wan X, Lu Q, Yi L. Zeng X, et al. Among authors: peng l. PLoS One. 2014 Feb 20;9(2):e88881. doi: 10.1371/journal.pone.0088881. eCollection 2014. PLoS One. 2014. PMID: 24586426 Free PMC article.

6

A review and comparison of methods for recreating individual patient data from published Kaplan-Meier survival curves for economic evaluations: a simulation study.

Wan X, Peng L, Li Y. Wan X, et al. Among authors: peng l. PLoS One. 2015 Mar 24;10(3):e0121353. doi: 10.1371/journal.pone.0121353. eCollection 2015. PLoS One. 2015. PMID: 25803659 Free PMC article.

7

Subgroup Economic Evaluation of Radiotherapy for Breast Cancer After Mastectomy.

Wan X, Peng L, Ma J, Chen G, Li Y. Wan X, et al. Among authors: peng l. Clin Ther. 2015 Nov 1;37(11):2515-2526.e5. doi: 10.1016/j.clinthera.2015.09.007. Epub 2015 Oct 21. Clin Ther. 2015. PMID: 26475419

8

Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives.

Wan XM, Peng LB, Ma JA, Li YJ. Wan XM, et al. Cancer. 2017 Jul 15;123(14):2634-2641. doi: 10.1002/cncr.30666. Epub 2017 Mar 16. Cancer. 2017. PMID: 28301684 Free article.

9

Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China.

Wan X, Zhang Y, Ma J, Tan C, Zeng X, Peng L. Wan X, et al. Among authors: peng l. Breast. 2019 Feb;43:1-6. doi: 10.1016/j.breast.2018.10.004. Epub 2018 Oct 16. Breast. 2019. PMID: 30342258

10

First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.

Wan X, Zhang Y, Tan C, Zeng X, Peng L. Wan X, et al. Among authors: peng l. JAMA Oncol. 2019 Apr 1;5(4):491-496. doi: 10.1001/jamaoncol.2018.7086. JAMA Oncol. 2019. PMID: 30789633 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9,979 results

Search Page

Filters